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In this case report, we describe the utilisation of two recently developed technologies for the successful
management of a persistent air leak (PAL) in a critically ill patient in whom cardiothoracic surgical
intervention was not possible. We report the case of a young leukaemic woman with a PAL complicating
Invasive Pulmonary Aspergillosis (IPA), who was effectively managed using an Endobronchial Valve,
supplemented by objective, digital air leak data provided by a Thopaz® device (Medela, Switzerland).
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).Case report
A 32-year old female with Acute Promyelocytic Leukaemia
(APML), previously treated by autogeneic haematopoietic stem cell
transplantation (HSCT), presented with pancytopaenia and evi-
dence of relapsed disease. She was started on IV Arsenic and All-
trans Retinoic Acid (ATRA) as a bridge to allogeneic HSCT, but
became pyrexial and increasingly oxygen-dependent. Serial chest
radiographs followed by thoracic Computed Tomography (CT)
scanning on Day 28 revealed progressive, extensive ground glass
opaciﬁcation (see Fig. 1(a)). Repeat CT imaging on Day 44 demon-
strated additional intrapulmonary mass lesions (see Fig. 1(b)).
Galactomannan titres (Aspergillus Antigen Index Value 0.89) and
subsequent bronchial lavage and pleural ﬂuid cultures would later
conﬁrm IPA secondary to Aspergillus Flavus.
The patient's illness was complicated by a left-sided tension
pneumothorax on Day 56. This prompted intercostal drain (ICD)
insertion (12F, Rocket Medical®) and ICU admission. Despite
appropriate antifungal and supportive therapies and a second ICD
(16F, Rocket Medical®) the patient's lung failed to re-expand.
Invasive mechanical ventilation was avoided and the patient
managed with high-level oxygen supplementation. Digital thoracic
drainage units (Thopaz®, Medela, Switzerland) demonstrated a
consistent PAL in excess of 2000 ml/min, likely due to a ruptured
fungal cavity in the lingular subsegment, which was demonstrated.
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Ltd. This is an open access article uon a third CT scan on Day 96 (see Fig. 2). The patient was deemed
unsuitable for thoracic surgical intervention due to excessive risk.
Since EBVs are not a licensed treatment for PAL in the UK National
Health Service, applications for funding and internal clinical
governance board approval were submitted on compassionate
grounds and approved.
Flexible bronchoscopy was initially attempted in ICU under
conscious sedation but was poorly tolerated. General anaesthesia
was therefore induced and the trachea intubated with manual IPPV
applied prior to bronchoscopy. A single 4.0 mm EBV (Zephyr 4.0®,
Pulmonx Inc. Neuchatel, Switzerland) was deployed into the lin-
gular segmental bronchus after inﬂation of a balloon catheter at
this site resulted in complete cessation of air leak. This effect was
carefully veriﬁed prior to EBV deployment using live air leak data
displayed on the Thopaz® unit attached to her 16F axillary drain.
This was corroborated by cessation of bubbling through the ante-
rior 12F drain circuit, which was attached to wall suction set
at 20 cm H20 pressure. The patient was extubated within one
hour of EBV deployment. The 16F axillary ICD was removed
12 h later having demonstrated no measurable air leak on the
Thopaz® device since the procedure.
Repeat CT imaging 2 weeks later demonstrated satisfactory
positioning of the EBV and signiﬁcant lung re-expansion (see
Fig. 3). The remaining 12F ICD was removed 2 weeks later,
following a 48-h period during which no measurable air leak had
been detected on Thopaz®. The patient expectorated the EBV 3
weeks later without any adverse effect and was eventually dis-
charged home following a 5-month admission. Prolonged anti-
fungal therapy and continuing IV Arsenic and ATRA are planned.nder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Fig. 1. Axial images from Thoracic Computed Tomography (CT) scans acquired in a 32-year old leukaemic patient with Invasive Pulmonary Aspergillosis (IPA). The selected images,
which are from identical slice positions, demonstrate bilateral ground glass opaciﬁcation on Day 21 ((a)) and new intrapulmonary fungal mass lesions, which had developed by the
time of repeat scanning on Day 47 ((b)).
Fig. 2. Selected axial (a) and coronal (b) images from a Thoracic Computed Tomog-
raphy (CT) scan acquired on Day 96 in a patient with Invasive Pulmonary Aspergillosis
(IPA). There is a left-sided tension pneumothorax and subcutaneous emphysema due
to a large alveolar-pleural ﬁstula resulting from rupture of a fungal mass lesion (*).
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molecular remission and she has been referred for allogeneic HSCT.
Discussion
Persistent air leak (PAL) can be devastating in patients with
signiﬁcant underlying lung disease or other co-morbidities, espe-
cially in mechanically-ventilated individuals. In bone marrow
transplant recipients particularly, air leaks are an ominous devel-
opment, with a mortality rate of 75% reported in a previous series,
in which death was commonly associated with IPA [1]. In this
context, direct air leak attenuation is extremely challenging due to
the typically poor physical condition of the patients affected and
the high risks associated with surgical management. Non-surgical
options include a Medical Pleurodesis, either by talc slurry or
autologous blood patch pleurodesis (ABPP). Neither was attempted
in this case given the marked failure of lung re-expansion. Talc
instillation may also result in severe pain in patients with benign
pleural disease and an irrevocable empyema in patients with
concomitant lung or pleural infection. ABPP is a painless procedure,Fig. 3. A single axial image from a Thoracic Computed Tomography (CT) scan acquired
on Day 110 in a leukaemic patient with Invasive Pulmonary Aspergillosis (IPA). A 4 mm
endobronchial valve (Zephyr®, Pulmonx Inc. Neuchatel, Switzerland) is demonstrated
within the lingular segmental bronchus proximal to an alveolar-pleural ﬁstula caused
by rupture of a fungal mass lesion. There has been a signiﬁcant improvement in the
previously demonstrated left-sided pneumothorax.
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leak following lung resection surgery, in spontaneous PTX [2,3] and
in mechanically-ventilated patients [4]. We were dissuaded from
ABPP by our patient's profound thrombocytopaenia, which would
have made coagulation and effective ‘patch’ formation at the site of
her air leak unlikely. Since ABPP may also result in drain occlusion
by clotted blood and tension PTX, it should also be used with
caution in patients with a high-volume PAL.
Given the limitations of these existing, non-surgical options for
directly attenuating PAL, management is often limited to continued
intercostal drainage and optimization of medical (e.g. infection,
nutrition) and ventilator factors where relevant (e.g. limiting tidal
volumes, minimizing mean airway pressures and facilitating
spontaneous (negative-pressure) breathing). However, these stra-
tegies rely on spontaneous healing and closure of the causative
broncho- and alveolar-pleural ﬁstula and they are unlikely to be
effective in leukaemic patients with IPA, in whom immunosup-
pressive and toxic oncolytic therapies are often run concurrently
and fungal clearance typically requires months of intensive treat-
ment [5]. EBVs offer a non-surgical, minimally-invasive alternative,
having been originally developed for endoscopic lung volume
reduction in emphysema [6]. Both of the currently available sys-
tems (Zephyr® EBV (Pulmonx Inc. Neuchatel, Switzerland)) and
Intrabronchial Valve (IBV®, Spiration Inc., Washington, USA) are
introduced through theworking channel of a ﬂexible bronchoscope
and utilise a unidirectional valve to prevent airﬂow into the
diseased area of lung. This results in collapse of distal lung paren-
chyma and attenuation of any air leak.
In the largest case-series to date, Travaline et al. described
complete or partial air leak cessation in 93% (n ¼ 37/40) of patients
treated with Zephyr® EBVs, including cases of spontaneous, post-
operative, traumatic and iatrogenic PTX. Median time from valve
insertion to ICD removal was 7.5 days [7]. Gillespie et al. reported
use of Respiration IBVs® in 7 patients with PAL related to secondary
spontaneous (3/7) and post-operative PTX (4/7); 75% (n ¼ 6) had
complete air leak cessation after a mean of 4.5 days, with ICD
removal after a median of 16 days [8]. There have also been indi-
vidual case reports and smaller series describing successful use of
EBVs to treat PAL complicating bacterial empyema, pneumonia and
ARDS [9e12] including a series of 3 mechanically-ventilated ICU
patients. In this series, EBV deployment facilitated rapid weaning
from ventilation or high-level oxygen supplementation [12], as was
possible in this case described here.
Digital thoracic drainage systems, such as the Thopaz® unit
(Medela, Switzerland) utilised here allow objective, real-time,
quantitative assessment of air leak via an ICD. Live digital air leak
data (ﬂow rate measured in ml/min) is displayed on a screen
incorporated into the device. Importantly, this data is also recorded
continuously, and presented as a graph of the preceding 24 h airleak data. This allows objective decisions to be made during EBV
deployment (regarding correct positioning of the device) and dur-
ing subsequent management, supplementing and potentially
replacing traditional subjective, qualitative assessments based on
the presence or absence of bubbling in the ICD bottle.
This brief report illustrates the considerable therapeutic utility
of EBVs in this context but also demonstrates the value of objective
air leak data in clinical decision-making in this setting, particularly
with regard to optimising EBV deployment and the removal of ICDs
in patients with life-threatening PTX. EBVs are a minimally-
invasive and potentially life-saving rescue therapy, which should
be considered in this setting and tested in a future prospective,
controlled study.Funding
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